The levels of IL-16 in fetal plasma at 16-24 weeks of gestation were very high, and decreased significantly by 25-36 weeks but at > 37 weeks remained significantly higher than adult levels. IL-16 transcripts were detectable in whole tissue extracts of fetal gut, skin and placenta but not in amniocytes, and IL-16 immunoreactivity was detectable in cells within the lamina propria of the fetal gut and within the skin, where it was associated with the basement membrane. Neither IL-16 levels nor chemotactic activity for CD4 + T cells in mid-pregnancy amniotic fluid was related to atopic outcomes at 1 year of age. IL-16 might have an important role in the early development of the human immune system and/or in regulating fetal and maternal immunological responsiveness during pregnancy.
Introduction
The major biological effect ascribed to interleukin-16 (IL-16), a soluble ligand for CD4, is as a chemoattractant for a wide range of CD4 + cells such as lymphocytes, 1 eosinophils, 2 monocytes/macrophages 3 and dendritic cells. 4 Interleukin-16 can activate CD4 + T cells if it is provided with IL-2. 5 In contrast, the pretreatment of CD4 + T cells with IL-16 reduces proliferation induced via T-cell receptor/CD3 cross-linking 6 and suppresses IL-2 production 7 while increasing the expression of CD25 (IL-2Ra) by CD4 + T cells and human leucocyte antigen-DR on CD4 + T cells and monocytes. 3 Interleukin-16 also inhibits the replication of human immunodeficiency virus type 1 8 and stimulates proinflammatory cytokine production by monocytes. 9 Interleukin-16 is produced by an ever-growing list of cell types including CD8 + and CD4 + T cells, 10, 11 epithelial cells, 12 dendritic cells, 4 monocytes, 13 synovial fibroblasts, 14 mast cells 15 and B cells. 16 More than 90% of circulating CD4 + and CD8 + T cells constitutively produce IL-16 although most of this is the 80 000 molecular weight, biologically inactive pro-IL-16. 11 Upon cellular activation, pro-IL-16 is cleaved to a monomer of 14 000-17 000 molecular weight that then forms biologically active tetramers. 17 Caspase 3, itself needing cleaving from the inactive pro-Caspase 3 form, mediates the cleavage of pro-IL-16. 18 Despite the well-established role for Caspase 3 in apoptosis and the release of IL-16, a link between secretion of active IL-16 and apoptosis has only been demonstrated for monocytes. 13 Given its chemotactic effect on CD4 + T and non-T cells it is not surprising that a role for IL-16 has been postulated for a number of diseases including acquired immune deficiency disease, 19 asthma, 20 rheumatoid arthritis 14 and systemic lupus erythematosus. 21 The role of IL-16 in normal physiology is also a focus of attention with IL-16 identified as having a potential role in the Catherine A. Thornton, 1 Judith A.
Holloway, 2 Janis K. Shute, 3 John W.
Holloway, 2 Norma D. Diaper 2 and
John O. Warner 
I M M U N O L O G Y O R I G I N A L A R T I C L E
trafficking of dendritic cells and the formation of dendritic cell and T-cell clusters, 4 as well as clusters including B cells. 16 Moreover, IL-16 can inhibit immunoglobulin E (IgE) production 22 and modify cytokine outputs by allergen-stimulated peripheral blood mononuclear cells including down-regulation of IL-5 and IL-13 but not IL-4 and up-regulation of interferon-c. 23 ,24 CD4-independent effects for IL-16 have been identified using CD4 knockout mice 25 and this is likely to lead to the elaboration of further roles for IL-16 in the immune response and immune homeostasis.
As the human fetal gut contains a large population of CD4 + cells from approximately 11 weeks of gestation 26 we postulated that the migration of these cells into the gut could occur under the influence of IL-16 swallowed in amniotic fluid. Furthermore, amniotic fluid IL-16 could similarly mediate the migration of CD4 + cells into the fetal skin, which is also exposed to this fluid. The presence of IL-16 in amniotic fluid has already been observed with a decline in levels over gestation and elevated levels in preterm and term amniotic fluid when there was evidence of microbial invasion of the amniotic cavity noted. 27 Circulating IL-16 is elevated in women with pre-eclampsia, 28, 29 and IL-16-positive microglia have been demonstrated in the human fetal brain from 11 to 20 weeks of gestation. 30 Tissue-specific, stage-dependent distribution of IL-16 at the materno-fetal interface has also been demonstrated during murine pregnancy. 31 We have therefore measured IL-16 (both protein and chemotactic activity) in amniotic fluid and evaluated the presence of CD4 + cells within both fetal gut and skin. Additional investigation has considered the possible sources of amniotic fluid IL-16 as well as the potential contribution of this cytokine to the subsequent development of an atopic phenotype.
Materials and methods
Tissue, blood and amniotic fluid samples Samples of human fetal gut (n = 12) and skin (n = 11) were obtained via the Medical Research Council tissue bank from suction or dilatation/evacuation terminations. Gestational age (last menstrual period) was determined anatomically by foot length. Tissue was snap frozen in liquid nitrogen and stored until use. Fetal blood was collected by umbilical vein or cardiac puncture from fetuses delivered for medical reasons using prostin (n = 8). Blood was also collected by umbilical vein puncture from neonates delivered at term (n = 17) and prematurely (n = 21), and by venepuncture from healthy adult controls (n = 16). Amniotic fluid and peripheral blood were collected using standard procedures from women undergoing diagnostic amniocentesis at 16-18 weeks of gestation (n = 20) and also from women undergoing elective Caesarean section at term (n = 16). Only amniotic fluid samples from pregnancies with no indication of fetal abnormality were included in this study. Cell-free amniotic fluid was prepared by centrifugation at 900 g and then stored at )80°until analysis. All bloods were collected into lithium heparin and plasma was obtained by centrifugation at 900 g for 10 min at room temperature. Plasma was filtered, divided into aliquots and stored at )80°until analysis. The study was approved by the Southampton and S.W. Hants Joint Research Ethics Committee and fulfilled the requirements of the Polkinghorne Committee report on the research use of fetuses and fetal tissues.
Immunohistochemistry
Tissue sections (8 lm) were cut at the cryostat onto poly-L-lysine-coated slides, air-dried and then fixed in acetone for 10 min at room temperature. After blocking in 0Á3% H 2 O 2 in 0Á1% sodium azide for 10 min, three 2-min washes in Tris-buffered saline and a further blocking incubation in 10% rabbit serum in Tris-buffered saline, 100 ll of primary antibody, at a preoptimized dilution, was applied to the slide for 30 min. The slides were washed as before and biotinylated rabbit anti-mouse immunoglobulins (Dako Ltd, Cambridge, UK) were applied for 30 min incubation at room temperature. After further washes, streptavidin biotin-peroxidase complexes (Dako Ltd) were applied for 30 min at room temperature before washing and the visualization of immunoreactivity with chromogen, either aminoethyl carbazole or diaminobenzidine (Biogenex, San Ramon, CA). Sections were counterstained with Mayer's haematoxylin, dehydrated and mounted in DPX (BDH, Dorset, UK) for viewing. Antibodies (at previously optimized concentrations) used were monoclonal antihuman CD3 (mIgG1, clone UCHT1; Dako Ltd), antihuman CD4 (mIgG1, Leu-3a; BD Biosciences, Oxford, UK), and anti-IL-16 (mIgG1, clone 15B2; Alexis, Nottingham, UK). An isotype control (mIgG1, clone MOPC-21; BD Biosciences) was always included.
IL-16 enzyme-linked immunosorbent assay
The IL-16 in amniotic fluid and plasma samples was measured using a commercially available IL-16-specific enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Biosource, Invitrogen, Oxford, UK). All samples were assayed at a dilution of 1 in 2 in the dilution buffer provided and the sensitivity of the assay was 23 pg/ml.
Chemotaxis assay

CD4
+ T cells were isolated from venous blood collected from healthy adult donors into lithium heparin. After preparation of peripheral blood mononuclear cells on Histopaque (Sigma, Dorset, UK), CD4 + T cells were isolated using the CD4 + T-cell isolation kit and LS+ columns for midiMACs (Miltenyi Biotec, Bisley, UK). The purity of the enriched population was assessed using flow cytometry (CELLQUEST on FACscan, BD Biosciences) and was routinely found to be > 95% CD4 + CD3 + T cells. Cells were washed and resuspended in RPMI-1640 with Glutamax, 100 U/ml penicillin, 100 lg/ml streptomycin and 0Á1% human serum albumin (chemotaxis assay buffer) at 2 · 10 6 cells/ml. T-cell chemotaxis was assayed using 5 lm pore polyvinylpyrrolidone-free polycarbonate filters (Costar; Corning Incorporated, Corning, NY) in micro-Boyden chambers. A serial dilution of recombinant human IL-16 (R&D Systems, Abingdon, UK) of 0Á1 pg/ml to 1 lg/ml was prepared in chemotaxis assay buffer and amniotic fluid was diluted (neat, 1/2, 1/10, 1/100) in chemotaxis assay buffer and added to the lower wells of the assay chamber in triplicate. The filter was fixed in place, enriched CD4 + T cells were added (100 000/well) and the chamber was incubated for 2 hr at 37°in 5% CO 2 in air. The filter was then removed, washed in phosphate-buffered saline and scraped to remove the cells on the upper surface of the filter, then the migrated cells adherent to the lower side were fixed in methanol and stained (Hema-Gurr; BDH). The numbers of cells in each of five high-power (· 400) fields were counted and the value obtained from control wells (buffer only) was subtracted. Neutralizing experiments were conducted by pretreating the sample (amniotic fluid final concentration 1 in 10) with goat polyclonal anti-IL-16 antibody (10 lg/ml final concentration; R&D Systems) for 45 min at room temperature. The ability to neutralize recombinant human IL-16 was assessed as a positive control. An isotype control (goat IgG; R&D Systems) at the same concentration was included.
Reverse transcription-polymerase chain reaction RNA was extracted from blood and tissue samples using RNase-free DNase treatment with the RNeasy total RNA isolation system as directed by the manufacturer (Qiagen Ltd, Crawley, UK). First strand complementary DNA (cDNA) synthesis was performed with 0Á5 lg of total RNA in a 20 ll reaction using the Omniscript reverse transcriptase kit (Qiagen Ltd.) primed with oligo-T 17 (AGC) (Sigma Genosys, Cambridge, UK), all as recommended by the manufacturer. RNA was preheated to 60°for 5 min to remove secondary structures, then placed on ice. Reverse transcription was carried out for 60 min at 37°.
Polymerase chain reactions (PCR) were performed in a total reaction volume of 25 ll using 1 ll of cDNA in buffer containing 10 mM Tris-HCl, pH 8Á3, 50 mM KCl, 0Á001% gelatin, with 2 mM MgCl 2 , 200 mM dNTP, 0Á2 lM of each primer and 0Á625 U Taq DNA polymerase (Sigma Genosys). For IL-16 PCR, amplification was performed with an initial denaturation of 94°for 2 min followed by 30 cycles of 94°for 20 seconds, 61°for 30 seconds, 72°w
ith a final extension of 72°for 10 min. Primers for IL-16 were: forward, 5 0 -GGCATCCATGTCACCATCTTA-3 0 , and reverse, 5 0 -AGACTGTGGCCTCTGCTGTAGA-3 0 . For b-actin, amplification was performed as above but with a final concentration of MgCl 2 of 1Á5 mM for 30 cycles at an annealing temperature of 54°with the primers for b-actin, forward, 5 0 -TGATATCGCCGCGCTCGT-3 0 , and reverse, 5 0 -CTCGGCCGTGGTGGTGAA-3 0 . Products were resolved on a 2% agarose gel, stained with ethidium bromide and imaged using a fluorimager 595 (Molecular Dynamics, GE Healthcare Ltd, Amersham, Buckinghamshire, UK).
Clinical evaluation
Clinical assessment of the infants was conducted at 1 year of age (by N.D.D. and J.O.W.). The children were weighed, measured and a physical examination was performed. Skin prick testing to Dermataphagoides pteronyssinus, Felix domesticus, grass pollen mix, tree pollen mix, cow's milk and hen's egg (ALK-Abello, Hørsholm, Denmark) was conducted on each child. A negative control (allergen diluent) and a positive control (10 mg/ml histamine; ALK) were always included. A child was considered atopic if a wheal of ! 3 mm was observed in response to any of the allergens used in the presence of an appropriate response to the positive and negative control. All the skin-prick-test-positive children included in the analysis also had eczema (n = 10) and the skin-prick-test-negative children were eczema-free (n = 10).
Statistics
Mann-Whitney U-test and Kruskall-Wallis were used for non-parametric statistical evaluation (SPSS version 10; SPSS Inc., Chicago, IL) for Windows software.
Results
Amniotic fluid IL-16
Amniotic fluid collected from women undergoing diagnostic amniocentesis at 16-18 weeks (n = 20) had significantly higher levels of immunoreactive IL-16 than amniotic fluid collected during elective Caesarean section at term (n = 16; P < 0Á001; Fig. 1a) .
Bioactivity of IL-16 in amniotic fluid was assessed using chemotaxis for adult CD4 + T cells. Chemotactic activity was significantly greater (P = 0Á0006) in amniotic fluid at 16-18 weeks of gestation compared to that collected at term (134Á76 ± 17Á67 cells per field of view for 16-18 weeks amniotic fluid diluted 1 in 2 versus 21Á79 ± 13Á53 cells per field of view for term amniotic fluid diluted 1 in 2; mean ± SEM; n = 6 per group). Chemotactic activity for CD4
+ cells was observed in early gestation amniotic fluid to a dilution of 1 in 100 (Fig. 1b) .
Neutralizing experiments were conducted with midpregnancy amniotic fluid using a goat polyclonal anti-IL-16 antibody. Lower levels of chemotactic activity for CD4 + T cells were observed in the presence of neutralizing anti-IL-16 antibody with each of the donors tested (n = 5; Fig. 1c) . Overall, the chemotactic activity of amniotic fluid for CD4 + T cells was significantly lower (P = 0Á0006) in the presence of neutralizing anti-IL-16 (42Á09 ± 6Á95%; mean ± SEM; n = 5) than in the absence of neutralizing antibody/presence of isotype control (99Á67 ± 7Á88%; mean ± SEM; n = 5). The isotype control antibody had a negligible effect on chemotaxis.
Source(s) of amniotic fluid IL-16
As the skin is semi-permeable until approximately 25 weeks of pregnancy when keratinization is complete 32 the fetal circulation may be a source of IL-16, which diffuses into the amniotic fluid. Circulating IL-16 levels in early gestation (16-24 weeks; n = 8) were the highest of all the plasma samples studied ( Fig. 2 ; median 770Á98 pg/ml, range 133Á79-2046Á88 pg/ml; P < 0Á001 in comparison to all other ages studied). Although levels decreased with increasing gestational age, circulating levels at 25-36 weeks (n = 21; median 100Á66 pg/ml, range 30Á19-230Á49 pg/ml; P < 0Á005) and at term (> 37 weeks gestation; n = 17; median 82Á19 pg/ml, range 26Á99-347Á76 pg/ml; P < 0Á005) remained significantly higher than in the adult (n = 16; median 34Á91 pg/ml, range 14Á12-505Á18 pg/ml).
The possible contribution of the fetal skin and gut to amniotic fluid IL-16 levels was then assessed. Interleukin-16-positive cells were present in the lamina propria of the fetal gut (Fig. 3a) and in the dermis of fetal skin IL-16 immunoreactivity was localized to the basement membrane of the epidermis (Fig. 3c) . To confirm these tissues as the source of IL-16 the expression of messenger RNA within whole tissue homogenates was examined. Transcripts for IL-16 were detected in fetal gut and skin at 13-16 weeks of gestation as well as in the placenta at 16-21 weeks of gestation, but not in amniocytes prepared from amniotic fluid (Fig. 4) . Adult CD4 + T cells were used as a positive control.
CD4 immunoreactivity in human fetal tissues
There was an abundance of CD4 + cells in the human fetal gut from as early as 11 weeks of gestation until at least 15 weeks of gestation (the latest time-point examined here; n = 12; Fig. 5a ) and the CD4 + cells were localized at the lumenal edge of the lamina propria. Human fetal skin at the same gestational age range had fewer CD4 + cells than the gut and immunoreactivity was not localized to the edge in contact with amniotic fluid (Fig. 5d ). There were far fewer CD3 + than CD4 + cells in the fetal gut and CD3 + cells were essentially absent from the fetal skin ( Fig. 5b,e) . Immunoreactivity was not seen in the isotype control treated samples of gut and skin (Fig. 5c,f) .
Amniotic fluid IL-16, chemotactic activity and atopic disease
The variability in both IL-16 levels and the contribution to the chemotactic effect of amniotic fluid on CD4 + T cells prompted us to investigate if the chemotactic properties of amniotic fluid and IL-16 levels within the fluid were associated with atopic disease development postnatally. There was no difference in either IL-16 levels (Fig. 6a) or chemotactic activity for CD4 + T cells (Fig. 6b ) in amniotic fluid collected at 16-18 weeks of gestation in infants who had a positive skin prick test at 1 year of age (n = 10) compared to those who remained skin-prick-test-negative (n = 10). There was no correlation between IL-16 protein levels and the chemotactic properties of the amniotic fluid sample (Spearman's r = 0Á291; not significant) either when analysing the sample series as a complete set, or separately for atopic versus non-atopic outcome.
Discussion
The abundance of CD4 + cells within fetal tissues prompted us to consider the possible role of IL-16 in mediating this infiltration into early gestation tissues. IL-16 was present in amniotic fluid obtained at a gestation similar to the fetal tissue samples (16-18 weeks of gestation) from women undergoing diagnostic amniocentesis. However, IL-16 was not detectable in term amniotic fluid samples collected from women undergoing elective Caesarean section. Another study has also reported a decline in human amniotic fluid IL-16 levels during gestation. 27 At approximately 25 weeks of gestation amniotic fluid undergoes a dramatic change in composition, as fetal urine becomes the major contributor. 32 Whether the decline in amniotic fluid IL-16 also occurs at this time needs to be assessed, although the limitations of working with samples from humans might make this difficult to ascertain. This is the first study to demonstrate that amniotic fluid IL-16 is biologically active. Chemotaxis assays using adult CD4 + T cells were used to evaluate if amniotic fluid IL-16 was biologically active. The bioassay results paralleled the immunoassay results, with the ability to induce the chemotaxis of adult CD4 + T cells being virtually restricted to mid-pregnancy amniotic fluid. Neutralizing experiments confirmed that IL-16 contributed to this activity, accounting for 58% of the response measured. Other chemokines have been identified within human amniotic fluid, namely IL-8 and RANTES (regulated on activation normal T cell-expressed and secreted). 33, 34 Although IL-8 is best known for its chemotactic effect on neutrophils, both it and RANTES can mediate the chemotaxis of T cells and may be contributing to the response we observed. 35 The contribution of other chemokines to this biological property of amniotic fluid remains to be evaluated.
Where does amniotic fluid IL-16 come from? We initially ruled out amniocytes (fetally derived cells in the amniotic fluid) showing that this population did not contain transcripts for IL-16. Fetal plasma could contribute to amniotic fluid IL-16 as the skin in early to mid-gestation readily allows diffusion. As fetal circulating IL-16 levels were very high at 16-24 weeks of gestation, corresponding with abundant levels of IL-16 in amniotic fluid at this time, there could be interchange of IL-16 between the circulation and the amniotic fluid.
Mirroring amniotic fluid levels, fetal circulating levels declined over gestation, although plasma levels at term (as well as earlier in gestation) remained significantly higher than in the adult circulation. In addition to the possible passive diffusion of IL-16 across the fetal gut and skin, cells within these tissues, and the placenta, could contribute to amniotic fluid IL-16. Immunoreactivity of IL-16 was observed in the gut and skin, implicating both of these sites as possible sources of amniotic fluid IL-16. The IL-16-positive cells were dispersed throughout both tissues but in the skin, although positive cells were observed throughout the dermis, IL-16 immunoreactivity was localized to the basement membrane of the forming epidermis. To confirm that cells within the gut and skin were producing IL-16 and not just storing amniotic fluidderived or fetal plasma-derived IL-16 we showed that transcripts for IL-16 were detectable within these tissues at the appropriate gestational ages. Caution should be employed in interpreting results from the placenta because it is difficult to wash all the blood out of this tissue and the IL-16 transcripts could reflect contamination with maternal or fetal blood cells. Only in situ hybridization and immunohistochemistry would allow identification of IL-16 production by cell populations within the placenta.
The observation of IL-16 localized to the epidermal basement membrane could have dramatic consequences for the biological activity of IL-16 at this site. The sequestering of a number of chemokines and cytokines by basement membranes has been observed, including macrophage inflammatory protein-1b and IL-4. 36, 37 Functionally, this sequestration could either limit the biological effect of the cytokine or generate very high local concentrations of biologically active mediator, depending on the nature of the proteoglycan core protein or glycosaminoglycan to which the cytokine is bound within the extracellular matrix. It is interesting that the association of IL-16 with the basement membrane did not occur in the fetal gut, suggesting that the extracellular matrix component to which IL-16 binds is differentially expressed in the gut and skin. Moreover, the one study of IL-16 messenger RNA expression in human adult skin found transcripts for this cytokine within the basal layer of the epidermis but unfortunately did not examine protein expression. 38 However, in mycosis fungoides IL-16 immunoreactivity was evident in the T cells infiltrating the skin but not in other cell types from the epidermis and dermis. 39 It will be necessary to conduct a direct comparison of fetal and adult skin to determine possible developmental differences in IL-16 expression within the skin.
From around 11 weeks of gestation the human fetal gut contains a large population of CD4 + cells that are localized at the lumenal edge of the lamina propria (Fig. 5a ). We did not further identify the CD4 + cells in the fetal gut because the focus of this investigation was IL-16 bioactivity and IL-16 interacts with the CD4 surface antigen irrespective of the cell type; however, work by others has shown that the majority of these CD4 + cells do not express CD3 and are likely to be macrophages. 26 The distribution of CD4 + cells at the lumenal edge suggests that these cells could be responding to chemoattractants, such as IL-16, within the amniotic fluid that the fetus swallows. If mediators within the amniotic fluid could influence CD4 + cell trafficking to the gut this effect might well extend to the skin, which is also exposed to amniotic fluid. Indeed, CD4 + cells were detectable within the fetal skin at equivalent gestational ages but the infiltrate of CD4 + cells was not as extensive in the fetal skin nor did it show localization to the tissue edge in contact with the amniotic fluid.
Extracellular matrix binding by IL-16 and attenuation of IL-16 bioactivity in the skin could explain the differences in abundance of CD4-positive cells at each site despite the skin being exposed to more IL-16. This difference could also be explained in a number of other ways. The skin and the gut might simply have different rates of development. The gut is considered structurally mature at 19 weeks of gestation which is earlier than the skin, where keratinization is not complete until approximately 25 weeks of gestation. 32, 40 Alternatively, biological assays of chemotactic factors indicate that these molecules characteristically have bell-shaped curves such that high doses no longer exert any chemotactic effect on the cell population being studied. As the skin has greater exposure to amniotic fluid than the gut, local concentrations in the skin might well be higher than in the gut and the chemotactic effect of IL-16 in the skin might, therefore, be limited. Finally, amniotic fluid IL-16 might not have a role in chemotaxis at this site. Interleukin-16 has many immunoregulatory properties including down-regulation of CD3-stimulated proliferation by T cells and IL-16 in amniotic fluid and the fetal circulation might be part of the immunoregulatory milieu of pregnancy that regulates maternal and fetal immune responsiveness. Naturally occurring CD4 + CD25 + regulatory T cells have been implicated in the maintenance of maternal immunological tolerance to the fetus 41 and IL-16 has been shown to favour the migration of this cell type and to induce expression of Forkhead box P3 (FoxP3). 42 All the babies born onto the study for which amniotic fluid was collected during amniocentesis are undergoing clinical follow-up for the development of atopic disease. As the first manifestations of atopic disease commonly occur in the gastrointestinal tract and/or skin during the first year after birth, the early development of both of these tissues might be critical to the later expression of disease. To date, a small number of 1-year-olds in this birth cohort have been identified as skin-prick-test-positive (with eczema) to common environmental allergens, i.e. atopic. Neither the levels of IL-16 nor the CD4 + T-cell chemotactic property of amniotic fluid from these infants differed from that of amniotic fluid from infants who remained skin-prick-testnegative (and eczema-free) at 1 year of age. Therefore, the IL-16 levels at 16-18 weeks of gestation do not differ with regard to the development of atopy by 1 year of age although the number included in this analysis is very small. Moreover, there was not a significant correlation between IL-16 levels and chemotactic properties of the amniotic fluid, suggesting that other chemoattractants variably contribute to the response observed and could differ between future atopic and non-atopic children. As chemokines and other molecules with chemoattracting properties might exert their influence on other non-CD4 + T-cell populations these might have a disease association.
This study shows that mid-gestation human amniotic fluid is an abundant source of immunoreactive IL-16, and neutralization studies reveal that this cytokine accounts for approximately 60% of the CD4 + T-cell chemotactic properties of human amniotic fluid at 16-18 weeks of gestation. Whether it is a biological mediator of chemotaxis by CD4 + T-cell and non-T-cell populations in the fetal gut in vivo remains to be determined, as does the identity of other chemoattractants within amniotic fluid that could contribute to this response. Numerous biological effects have now been described for IL-16, and as IL-16 can stimulate the production of proinflammatory cytokines by monocytes and support the migration of Langerhans cells harvested from CD4 knockout mice it is likely to have additional CD4-independent effects. 25, 43 The abundance of IL-16 in early pregnancy amniotic fluid as well as in the fetal circulation throughout gestation might modify fetal and neonatal immunological functions. Understanding these mechanisms will aid in the identification of perturbations that might contribute to the development of various diseases, especially those that are first manifest in childhood.
